TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02145936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
Study: NCT03861338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade
Description: The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
Study: NCT02327767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resonating Arm Exerciser
Description: Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
Study: NCT04028778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
Study: NCT03005145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of adequate antibiotic treatment
Description: The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of adequate antibiotic treatment.
Description: The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
Study: NCT00385710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Depakine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05764421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor-cognitive intervention
Description: The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
Study: NCT03809676

Intervention type: OTHER
Intervention: periodontal examination
Description: clinical measurements were recorded

Intervention type: OTHER
Intervention: periodontal examination
Description: clinical measurements were recorded
Study: NCT03398785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular chemical Ablation of Adrenal Gland
Description: Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
Study: NCT01737320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short-course antibiotic treatment
Description: On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: accepted prolonged antibiotic treatment
Study: NCT01188421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: up to 8/2 mg Sublingual (SL) per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: up to 0.8 mg per day (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol ER
Description: up to 600 mg per day
Study: NCT00705289

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab used in line with current clinical practice and local guidelines.
Study: NCT03144947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab IV
Description: Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC
Description: Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.
Study: NCT03293498

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD - Day 0
Description: Vaccine
Study: NCT03144947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
Study: NCT02662829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study: NCT03055156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low rebound mattress toppers
Description: Patients will sleep on this mattress topper during their diagnostic sleep study.
Study: NCT03293498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD - Day 21
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD - Day 21
Description: Vaccine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline - Day 21
Description: Placebo
Study: NCT01917097

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT01304342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intranasal fentanyl 200 micrograms 5 min before the ERCP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline intravenously and intranasally
Study: NCT03036813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voxelotor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voxelotor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04333355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
Study: NCT02928224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Orally, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Standard of care.
Study: NCT00813059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Description: Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
Study: NCT02961010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keeping Safe
Description: A whole school Preventative Education programme
Study: NCT03009136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCRT
Description: composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
Study: NCT01179334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Participants continued to take daily stable sildenafil background treatment according to their prescriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
Study: NCT02115139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
Study: NCT04415528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Mindfulness Therapy
Description: EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Mindfulness Therapy
Description: EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention.
Study: NCT04402008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Once Daily Dosing
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Twice Daily Dosing
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study: NCT01064193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
Study: NCT02358369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost sustained release Ocular Insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost sustained release Ocular Insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Description: Bimatoprost sustained release Ocular Insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: BID drops OU, 0.5% ophthalmic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Ocular Insert
Description: Placebo ocular insert OU.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Ocular Insert
Description: Placebo ocular insert OU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ocular Insert
Description: Placebo ocular insert OU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eye Drops
Description: Placebo eye drops BID OU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eye Drops
Description: Placebo eye drops BID OU.
Study: NCT02152670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Methyl Para Tyrosine (AMPT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]PHNO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]PHNO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]PHNO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]raclopride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Study: NCT04385914

Intervention type: OTHER
Intervention: COVID positive via testing
Description: Following pregnancy outcomes whether they are COVID positive or negative

Intervention type: OTHER
Intervention: COVID positive via testing
Description: Following pregnancy outcomes whether they are COVID positive or negative
Study: NCT03716986

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI Oxygen Saturation Map
Description: Calculation of the oxygen saturation map of gliomas cases
Study: NCT02456545

Intervention type: OTHER
Intervention: ≥ 1 potential risk factor for BD
Description: exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)

Intervention type: OTHER
Intervention: depressive syndrome
Description: in- and outpatients with depressive syndrome

Intervention type: OTHER
Intervention: ADHD
Description: in- and outpatients with ADHD
Study: NCT00651404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
Study: NCT03205826

Intervention type: OTHER
Group type: OTHER
Intervention: Type of sedation used
Description: All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
Study: NCT03458832

Intervention type: DIAGNOSTIC_TEST
Intervention: FSHD-specific functional rating scale
Description: The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.

Intervention type: DEVICE
Intervention: Electrical Impedance Myography
Description: EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
Study: NCT03501745

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WeChat
Description: Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WeChat
Description: Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
Study: NCT02047630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic latanoprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brand-name latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand-name latanoprost
Study: NCT03616327

Intervention type: DEVICE
Group type: OTHER
Intervention: MATRx in-lab, MATRx plus
Description: The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
Study: NCT03982303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.
Study: NCT02024191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Study: NCT03816410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAA amputation
Description: complete surgical amputation of the left atrial appendage
Study: NCT00235690

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draws
Description: PK samples obtained around a clinical dosing of colistin

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: PK blood samples will be obtained around a clinical dosing of colistin